Hossein Ouranos, MD
Interventional Cardiology · Iowa City, IANPI 1790122935
Payments from drug & device makers
What this record shows
This record is dominated by grants: $22,000 of the $27,710 with a category attached, or 79.4%. Medtronic accounts for 82.6% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2021 at $22,626 and has fallen 99.4% since, to $136 in 2025.
Across 130 payments — averaging $213.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$23K
- Boston Scientific$2K
- Penumbra, Inc.$1K
- Edwards Lifesciences$590
- Abbott$172
- Johnson & Johnson$171
- plus $784 from 14 others
What the payments were for
- Grants$22,00079%
- Travel & lodging$2,86210%
- Food & beverage$2,84810%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 22 | $22,901 |
| Boston Scientific | 36 | $2,058 |
| Penumbra, Inc. | 2 | $1,035 |
| Edwards Lifesciences | 7 | $590 |
| Abbott | 5 | $172 |
| Johnson & Johnson(2 entities) | 10 | $171 |
| Merck | 8 | $125 |
| AstraZeneca | 8 | $120 |
| E.r. Squibb & Sons, L.L.C. | 6 | $81 |
| Boehringer Ingelheim | 5 | $79 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $67 |
| Amgen | 4 | $59 |
| Acist Medical Systems, Inc. | 2 | $51 |
| Novartis | 2 | $40 |
| Novo Nordisk | 2 | $40 |
| Shockwave Medical, Inc | 2 | $35 |
| Philips North America LLC | 2 | $33 |
| Lantheus Medical Imaging, Inc. | 1 | $25 |
| Chiesi USA, Inc. | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$22,000
- VersaCross Access Solution$1,146
- Indigo System$1,035
- COREVALVE EVOLUT R$381
- WATCHMAN FLX$143
- Watchman$101
How this compares
$27,710 in reported general payments places this provider in the 85th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 138 | $133,741 |
| EntrestoSacubitril/Valsartan | 28 | $42,188 |
| FarxigaDapagliflozin Propanediol | 29 | $36,705 |
| XareltoRivaroxaban | 26 | $23,412 |
| BrilintaTicagrelor | 24 | $19,775 |
| JardianceEmpagliflozin | 11 | $9,490 |
| Metoprolol Succinate | 116 | $2,128 |
| Valsartan | 40 | $1,506 |
| Rosuvastatin Calcium | 71 | $1,497 |
| Atorvastatin Calcium | 111 | $1,134 |
| Ezetimibe | 65 | $911 |
| ClopidogrelClopidogrel Bisulfate | 39 | $715 |
| Amlodipine Besylate | 83 | $510 |
| Nitroglycerin | 45 | $496 |
| Metoprolol Tartrate | 62 | $474 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Brilinta | $120 | $56,48053 claims |
| NovartisEntresto | $40 | $42,18828 claims |
| Johnson & JohnsonXarelto | $171 | $23,41226 claims |
| Boehringer IngelheimJardiance | $79 | $9,49011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Iowa City
- Jason AllenIowa City$30K
- Spas KotevIowa City$12K
- Waqas SiddiquiIowa City$10K
- Hisham IbrahimIowa City$8K
- Yehia SalehIowa City$6K
- James RossenIowa City$5K
- Connor YoungIowa City$4K
- Vikram SharmaIowa City$3K
- Phillip HorwitzIowa City$3K
- Ahmad ArhamIowa City$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.